Eli Lilly (LLY) Profitability Comparisons, Net Margin, Gross Margin, Tax rate, Cash Flow Margin Comparisons - CSIMarket
CSIMarket
 


Eli Lilly And Company  (NYSE: LLY)

Eli Lilly Profitability Comparisons

Select each Category to receive further Information




LLY Profitability Ratio

Company Industry Sector S&P 500
Gross Profit Margin (Q1 MRQ) 81.93 % 70.86 % 67.38 % 46.15 %
Gross Margin (Q1 TTM) 82.83 % 71.39 % 67.8 % 46.36 %
Gross Profit Margin 5 Yr. Avg. 78.91 % 67.81 % 65.55 % 48.95 %
EBITDA Margin (Q1 MRQ) 47.27 % 21.18 % 18.45 % 20.46 %
EBITDA Margin (Q1 TTM) 45.91 % 25.13 % 20.78 % 20.1 %
EBITDA Margin 5 Yr. Avg. 30.94 % 47.09 % 31.38 % 23.39 %
Operating Margin (Q1 MRQ) 47.98 % 17.04 % 16.52 % 16.05 %
Operating Margin (Q1 TTM) 46.29 % 20.45 % 17.83 % 16.34 %
Operating Margin 5 Yr. Avg. 31.64 % 15.37 % 14.33 % 19.26 %
Pre-Tax Profit Margin (Q1 MRQ) 44.7 % 13.42 % 10.72 % 13.96 %
Pre-Tax Profit Margin (Q1 TTM) 43.08 % 16.68 % 12.68 % 13.09 %
Pre-Tax Profit Margin 5 Yr. Avg. 26.48 % 12.98 % 10.37 % 13.52 %
Net Margin (Q1 MRQ) 37.36 % 9.91 % 8.02 % 11.42 %
Net Margin (Q1 TTM) 34.99 % 13.16 % 9.86 % 10.76 %
Net Margin 5 Yr. Avg. 22.42 % 5.79 % 6.08 % 10.8 %



Business Segment Profit Margin
 
U S
  Explore U S Segment  -
Outside U S
  Explore Outside U S Segment  -
Cardiometabolic Health
  Explore Cardiometabolic Health Segment  -
Cardiometabolic Health U S
  Explore Cardiometabolic Health U S Segment  -
Cardiometabolic Health Outside U S
  Explore Cardiometabolic Health Outside U S Segment  -
Mounjaro
  Explore Mounjaro Segment  -
Mounjaro U S
  Explore Mounjaro U S Segment  -
Mounjaro Outside U S
  Explore Mounjaro Outside U S Segment  -
Trulicity
  Explore Trulicity Segment  -
Trulicity U S
  Explore Trulicity U S Segment  -
Trulicity Outside U S
  Explore Trulicity Outside U S Segment  -
Zepbound
  Explore Zepbound Segment  -
Zepbound U S
  Explore Zepbound U S Segment  -
Jardiance
  Explore Jardiance Segment  -
Jardiance U S
  Explore Jardiance U S Segment  -
Jardiance Outside U S
  Explore Jardiance Outside U S Segment  -
Other cardiometabolic health
  Explore Other cardiometabolic health Segment  -
Other cardiometabolic health U S
  Explore Other cardiometabolic health U S Segment  -
Other cardiometabolic health Outside U S
  Explore Other cardiometabolic health Outside U S Segment  -
Oncology
  Explore Oncology Segment  -
Oncology U S
  Explore Oncology U S Segment  -
Oncology Outside U S
  Explore Oncology Outside U S Segment  -
Verzenio
  Explore Verzenio Segment  -
Verzenio U S
  Explore Verzenio U S Segment  -
Verzenio Outside U S
  Explore Verzenio Outside U S Segment  -
Other oncology
  Explore Other oncology Segment  -
Other oncology U S
  Explore Other oncology U S Segment  -
Other oncology Outside U S
  Explore Other oncology Outside U S Segment  -
Immunology
  Explore Immunology Segment  -
Immunology U S
  Explore Immunology U S Segment  -
Immunology Outside U S
  Explore Immunology Outside U S Segment  -
Taltz
  Explore Taltz Segment  -
Taltz U S
  Explore Taltz U S Segment  -
Taltz Outside U S
  Explore Taltz Outside U S Segment  -
Other immunology
  Explore Other immunology Segment  -
Other immunology U S
  Explore Other immunology U S Segment  -
Other immunology Outside U S
  Explore Other immunology Outside U S Segment  -
Neuroscience
  Explore Neuroscience Segment  -
Neuroscience U S
  Explore Neuroscience U S Segment  -
Neuroscience Outside U S
  Explore Neuroscience Outside U S Segment  -
Other
  Explore Other Segment  -
Other U S
  Explore Other U S Segment  -
Other Outside U S
  Explore Other Outside U S Segment  -
Europe
  Explore Europe Segment  -
Japan
  Explore Japan Segment  -
China
  Explore China Segment  -
Net product revenue
  Explore Net product revenue Segment  -
Collaboration and other revenue
  Explore Collaboration and other revenue Segment  -
U S Sales returns rebates and discounts
  Explore U S Sales returns rebates and discounts Segment  -
Zepbound Outside U S
  Explore Zepbound Outside U S Segment  -
Rest of world
  Explore Rest of world Segment  -
Reportable Segment
  Explore Reportable Segment Segment  37.36 %
 

Company's Cashflow Profitability & Other



Profitability Ratios Company Industry Sector S&P 500
Free Cash Flow Margin (Q1 MRQ) 15.19 % -0.01 % 0.22 % 1.39 %
Free Cash Flow Margin (Q1 TTM) 16.36 % 17.47 % 13.83 % 9.08 %
Free Cash Flow Margin 5 Yr. Avg. - 19.28 % 14.86 % 15.58 %
Net Cash Flow Margin (Q1 MRQ) -10.03 % 0.02 % -0.02 % 0.13 %
Net Cash Flow Margin (Q1 TTM) 3.03 % -0.36 % 0.15 % 1.85 %
Net Cash Flow Margin 5 Yr. Avg. - 4.38 % 3.16 % 6.44 %
Effective Tax Rate (Q1 MRQ) 16.43 % 25.94 % 25.04 % 18.8 %
Effective Tax Rate (Q1 TTM) 18.79 % 21.36 % 23 % 19.44 %
Effective Tax Rate 5 Yr. Avg. 14.78 % 15.08 % 20.51 % 19.76 %
Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.